Pekkurnaz, Gulcin
Wang, Xinnan http://orcid.org/0000-0002-2640-7082
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM128823, RO1GM143258)
Parkinson’s Foundation (PF-JFA-1888)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (RO1NS089583)
Article History
Received: 19 January 2022
Accepted: 23 May 2022
First Online: 11 July 2022
Competing interests
: X. W. is a co-founder, adviser, and shareholder of AcureX Therapeutics, and a shareholder of Mitokinin Inc. Both companies develop therapeutics that target mitochondria for neurodegenerative diseases. G. P. declares no competing interests.